

Supplementary Table 1. Trial design and demographics of glucagon-like peptide 1 receptor agonist cardiovascular outcome trials

Variable	LEADER	SUSTAIN-6	EXSCEL
Trial characteristics			
Year reported	2016	2016	2017
No. of participants	9,340	3,297	14,752
Median follow-up, yr	3.8	2.1	3.2
Eligibility criteria	Patients with type 2 diabetes mellitus who had a glycated hemoglobin level of 7.0% or more, with an age of 50 years or more with at least one cardiovascular coexisting condition or an age of 60 years or more with at least one cardiovascular risk factor.	Patients with type 2 diabetes mellitus who had a glycated hemoglobin level of 7.0% or more, with an age of 50 years or more with established cardiovascular disease, chronic heart failure, or chronic kidney disease of stage 3 or higher or an age of 60 years or more with at least one cardiovascular risk factor.	Adults with type 2 diabetes mellitus with glycated hemoglobin level of 6.5 to 10.0%. The trial was designed such that approximately 70% of enrolled patients would have had previous cardiovascular events and 30% would not have previous cardiovascular events.
Demographics			
Age, yr	64.3±7.20	64.6±7.4	62.0±8.89
Female sex	3,337 (35.7)	1,295 (39.3)	5,603 (38.0)
Duration of diabetes, yr	12.9±8.05	13.9±8.1	12.0±7.79
HbA1c, %	8.7±1.55	8.7±1.5	8.0±1.19
Body weight, kg	91.7±21.00	92.1±20.6	NR
BMI, kg/m ²	32.5±6.30	32.8±6.2	31.8±5.89
Race			
White	7,238 (77.5)	2,736 (83.0)	11,175 (75.8)
Black	777 (8.3)	221 (6.7)	878 (6.0)
Asian	936 (10.0)	273 (8.3)	1,452 (9.8)
Other	389 (4.2)	67 (2.0)	1,242 (8.4)
Geographic region			
Europe	3,296 (35.3)	632 (19.2)	6,788 (46.0)
North America	2,847 (30.5)	1,137 (34.5)	3,708 (25.1)
Asia	711 (7.6)	1,528 (46.3) ^a	1,529 (10.4)
Rest of the world	2,486 (26.6)		2,727 (18.5)
Systolic BP, mm Hg	135.9±17.75	135.6±17.2	NR
Diastolic BP, mm Hg	77.1±10.20	77.0±10.0	NR
Pulse, beats/min	NR	72.0±10.9	NR
LDL-C, mg/dL	NR	82.3±45.6	NR
HDL-C, mg/dL	NR	43.7±27.1	NR
Never smoked	NR	1,493 (45.3)	7,233 (49.0)
Medical history			
Established CVD	7,598 (81.3)	2,735 (83.0)	10,782 (73.1)
Risk factors for CVD	1,742 (18.7)	562 (17.0)	3,970 (26.9)

(Continued to the next page)

Supplementary Table 1. Continued

Variable	LEADER	SUSTAIN-6	EXSCEL
Renal function			
eGFR \geq 90	3,275 (35.1)	990 (30.0)	4,268 (28.9)
60–90	3,907 (41.8)	1368 (41.5)	7,246 (49.1)
30–59	1,934 (20.7)	832 (25.2)	3,177 (21.5)
<30	224 (2.4)	107 (3.3)	14 (0.1)
Medication history			
Insulin user	4,169 (44.6)	1,913 (58.0)	6,836 (46.3)
Antihypertensives	8,632 (92.4)	3,082 (93.5)	13,323 (90.3) ^b
Lipid-lowering agents	7,079 (75.8)	2,521 (76.5)	11,370 (77.0)
Antithrombotic/anticoagulants	6,326 (67.7) ^c	2514 (76.3)	10,835 (73.4)

Values are presented as mean \pm standard deviation or number (%).

LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6, Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes; EXSCEL, Exenatide Study of Cardiovascular Event Lowering Trial; HbA_{1c}, glycosylated hemoglobin; NR, not reported; BMI, body mass index; BP, blood pressure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate.

^aSUSTAIN-6 trial did not report Asian data as a single geographic region, ^bAntihypertensive, antianginal, and other cardiovascular medications, ^cIncluding only platelet aggregation inhibitors.